A double-blind, delayed-start trial of rasagiline in Parkinson's disease

C. Warren Olanow, Olivier Rascol, Robert Hauser, Paul D. Feigin, Joseph Jankovic, Anthony Lang, William Langston, Eldad Melamed, Werner Poewe, Fabrizio Stocchi, Eduardo Tolosa

Research output: Contribution to journalArticle

598 Citations (Scopus)

Abstract

BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease. METHODS: In this double-blind trial, we examined the possibility that rasagiline has diseasemodifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 mg or 2 mg per day) for 36 weeks (the delayed-start group). To determine a positive result with either dose, the early-start treatment group had to meet each of three hierarchical end points of the primary analysis based on the Unified Parkinson's Disease Rating Scale (UPDRS, a 176-point scale, with higher numbers indicating more severe disease): superiority to placebo in the rate of change in the UPDRS score between weeks 12 and 36, superiority to delayed-start treatment in the change in the score between baseline and week 72, and noninferiority to delayed-start treatment in the rate of change in the score between weeks 48 and 72. RESULTS: Early-start treatment with rasagiline at a dose of 1 mg per day met all end points in the primary analysis: a smaller mean (±SE) increase (rate of worsening) in the UPDRS score between weeks 12 and 36 (0.09±0.02 points per week in the early-start group vs. 0.14±0.01 points per week in the placebo group, P=0.01), less worsening in the score between baseline and week 72 (2.82±0.53 points in the early-start group vs. 4.52±0.56 points in the delayed-start group, P=0.02), and noninferiority between the two groups with respect to the rate of change in the UPDRS score between weeks 48 and 72 (0.085±0.02 points per week in the early-start group vs. 0.085±0.02 points per week in the delayed-start group, P

Original languageEnglish
Pages (from-to)1268-1278
Number of pages11
JournalNew England Journal of Medicine
Volume361
Issue number13
DOIs
Publication statusPublished - Sep 24 2009

Fingerprint

Parkinson Disease
Placebos
Therapeutics
Disease Progression
rasagiline

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., ... Tolosa, E. (2009). A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New England Journal of Medicine, 361(13), 1268-1278. https://doi.org/10.1056/NEJMoa0809335

A double-blind, delayed-start trial of rasagiline in Parkinson's disease. / Olanow, C. Warren; Rascol, Olivier; Hauser, Robert; Feigin, Paul D.; Jankovic, Joseph; Lang, Anthony; Langston, William; Melamed, Eldad; Poewe, Werner; Stocchi, Fabrizio; Tolosa, Eduardo.

In: New England Journal of Medicine, Vol. 361, No. 13, 24.09.2009, p. 1268-1278.

Research output: Contribution to journalArticle

Olanow, CW, Rascol, O, Hauser, R, Feigin, PD, Jankovic, J, Lang, A, Langston, W, Melamed, E, Poewe, W, Stocchi, F & Tolosa, E 2009, 'A double-blind, delayed-start trial of rasagiline in Parkinson's disease', New England Journal of Medicine, vol. 361, no. 13, pp. 1268-1278. https://doi.org/10.1056/NEJMoa0809335
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New England Journal of Medicine. 2009 Sep 24;361(13):1268-1278. https://doi.org/10.1056/NEJMoa0809335
Olanow, C. Warren ; Rascol, Olivier ; Hauser, Robert ; Feigin, Paul D. ; Jankovic, Joseph ; Lang, Anthony ; Langston, William ; Melamed, Eldad ; Poewe, Werner ; Stocchi, Fabrizio ; Tolosa, Eduardo. / A double-blind, delayed-start trial of rasagiline in Parkinson's disease. In: New England Journal of Medicine. 2009 ; Vol. 361, No. 13. pp. 1268-1278.
@article{ef8815bf1044458ca63e6122eccc84c3,
title = "A double-blind, delayed-start trial of rasagiline in Parkinson's disease",
abstract = "BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease. METHODS: In this double-blind trial, we examined the possibility that rasagiline has diseasemodifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 mg or 2 mg per day) for 36 weeks (the delayed-start group). To determine a positive result with either dose, the early-start treatment group had to meet each of three hierarchical end points of the primary analysis based on the Unified Parkinson's Disease Rating Scale (UPDRS, a 176-point scale, with higher numbers indicating more severe disease): superiority to placebo in the rate of change in the UPDRS score between weeks 12 and 36, superiority to delayed-start treatment in the change in the score between baseline and week 72, and noninferiority to delayed-start treatment in the rate of change in the score between weeks 48 and 72. RESULTS: Early-start treatment with rasagiline at a dose of 1 mg per day met all end points in the primary analysis: a smaller mean (±SE) increase (rate of worsening) in the UPDRS score between weeks 12 and 36 (0.09±0.02 points per week in the early-start group vs. 0.14±0.01 points per week in the placebo group, P=0.01), less worsening in the score between baseline and week 72 (2.82±0.53 points in the early-start group vs. 4.52±0.56 points in the delayed-start group, P=0.02), and noninferiority between the two groups with respect to the rate of change in the UPDRS score between weeks 48 and 72 (0.085±0.02 points per week in the early-start group vs. 0.085±0.02 points per week in the delayed-start group, P",
author = "Olanow, {C. Warren} and Olivier Rascol and Robert Hauser and Feigin, {Paul D.} and Joseph Jankovic and Anthony Lang and William Langston and Eldad Melamed and Werner Poewe and Fabrizio Stocchi and Eduardo Tolosa",
year = "2009",
month = "9",
day = "24",
doi = "10.1056/NEJMoa0809335",
language = "English",
volume = "361",
pages = "1268--1278",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "13",

}

TY - JOUR

T1 - A double-blind, delayed-start trial of rasagiline in Parkinson's disease

AU - Olanow, C. Warren

AU - Rascol, Olivier

AU - Hauser, Robert

AU - Feigin, Paul D.

AU - Jankovic, Joseph

AU - Lang, Anthony

AU - Langston, William

AU - Melamed, Eldad

AU - Poewe, Werner

AU - Stocchi, Fabrizio

AU - Tolosa, Eduardo

PY - 2009/9/24

Y1 - 2009/9/24

N2 - BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease. METHODS: In this double-blind trial, we examined the possibility that rasagiline has diseasemodifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 mg or 2 mg per day) for 36 weeks (the delayed-start group). To determine a positive result with either dose, the early-start treatment group had to meet each of three hierarchical end points of the primary analysis based on the Unified Parkinson's Disease Rating Scale (UPDRS, a 176-point scale, with higher numbers indicating more severe disease): superiority to placebo in the rate of change in the UPDRS score between weeks 12 and 36, superiority to delayed-start treatment in the change in the score between baseline and week 72, and noninferiority to delayed-start treatment in the rate of change in the score between weeks 48 and 72. RESULTS: Early-start treatment with rasagiline at a dose of 1 mg per day met all end points in the primary analysis: a smaller mean (±SE) increase (rate of worsening) in the UPDRS score between weeks 12 and 36 (0.09±0.02 points per week in the early-start group vs. 0.14±0.01 points per week in the placebo group, P=0.01), less worsening in the score between baseline and week 72 (2.82±0.53 points in the early-start group vs. 4.52±0.56 points in the delayed-start group, P=0.02), and noninferiority between the two groups with respect to the rate of change in the UPDRS score between weeks 48 and 72 (0.085±0.02 points per week in the early-start group vs. 0.085±0.02 points per week in the delayed-start group, P

AB - BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease. METHODS: In this double-blind trial, we examined the possibility that rasagiline has diseasemodifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 mg or 2 mg per day) for 36 weeks (the delayed-start group). To determine a positive result with either dose, the early-start treatment group had to meet each of three hierarchical end points of the primary analysis based on the Unified Parkinson's Disease Rating Scale (UPDRS, a 176-point scale, with higher numbers indicating more severe disease): superiority to placebo in the rate of change in the UPDRS score between weeks 12 and 36, superiority to delayed-start treatment in the change in the score between baseline and week 72, and noninferiority to delayed-start treatment in the rate of change in the score between weeks 48 and 72. RESULTS: Early-start treatment with rasagiline at a dose of 1 mg per day met all end points in the primary analysis: a smaller mean (±SE) increase (rate of worsening) in the UPDRS score between weeks 12 and 36 (0.09±0.02 points per week in the early-start group vs. 0.14±0.01 points per week in the placebo group, P=0.01), less worsening in the score between baseline and week 72 (2.82±0.53 points in the early-start group vs. 4.52±0.56 points in the delayed-start group, P=0.02), and noninferiority between the two groups with respect to the rate of change in the UPDRS score between weeks 48 and 72 (0.085±0.02 points per week in the early-start group vs. 0.085±0.02 points per week in the delayed-start group, P

UR - http://www.scopus.com/inward/record.url?scp=70349456475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349456475&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa0809335

DO - 10.1056/NEJMoa0809335

M3 - Article

C2 - 19776408

AN - SCOPUS:70349456475

VL - 361

SP - 1268

EP - 1278

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 13

ER -